LNTH Q4 2024 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$391M+10.5% YoY

Gross Profit

$249M63.5% margin

Operating Income

$114M29.1% margin

Net Income

-$12M-3.0% margin

EPS (Diluted)

$-0.17

QoQ Revenue Growth

+3.3%

Cash Flow

Operating Cash Flow

$155M

Free Cash Flow

$139M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$892M

Stockholders' Equity

$1.1B

Cash & Equivalents

$913M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$391M	$354M	+10.5%
Gross Profit	$249M	$230M	+8.1%
Operating Income	$114M	$137M	-17.2%
Net Income	-$12M	$103M	-111.4%

Revenue Segments

Product

$388M33%

PYLARIFY

$266M23%

Radiopharmaceutical Oncology

$266M23%

Total Precision Diagnostics

$117M10%

DEFINITY

$86M7%

Techne Lite

$25M2%

Strategic Partnerships And Other

$8M1%

Other Precision Diagnostics

$6M1%

License and Royalty Revenues

$3M0%